Ritter, V., Krautter, F., Klein, D., Jendrossek, V., & Rudner, J. (2022). Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. Nature Publishing Group.
Chicago Style CitationRitter, Violetta, Franziska Krautter, Diana Klein, Verena Jendrossek, and Justine Rudner. Correction To: Bcl-2/Bcl-xL Inhibitor ABT-263 Overcomes Hypoxia-driven Radioresistence and Improves Radiotherapy. Nature Publishing Group, 2022.
MLA CitationRitter, Violetta, et al. Correction To: Bcl-2/Bcl-xL Inhibitor ABT-263 Overcomes Hypoxia-driven Radioresistence and Improves Radiotherapy. Nature Publishing Group, 2022.
Warning: These citations may not always be 100% accurate.